Triazavirin

DB15622InvestigationalSmall molecule

Triazavirin is an antiviral used to treat several strains of influenza. Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.

Mechanism: Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis.
Curator reviewed · 2 references
Primary indication: Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.Curator reviewed
Formula / weight: C₅H₄N₆O₃S · 228.19 g/mol (avg)
Also known as: Riamilovir

Resolves to

Compound

UNIIF2HTG1MH2DCAS123606-06-4ChEMBLCHEMBL1618116

Clinical / RWD

ATCJ05AX32

Structure

InChIKeyIDVQGNMSSHPZSJ-UHFFFAOYSA-NSMILESCSC1=NN2C(NN=C(C2=O)[N+]([O-])=O)=N1

What you can answer from here — as of March 06, 2025

2Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 6 drug categories

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of Triazavirin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account